Heparan sulfate in cerebrospinal fluid as a biomarker to assess disease severity and for treatment monitoring in patients with Mucopolysaccharidosis Type II: a position statement.
Saved in:
| Title: | Heparan sulfate in cerebrospinal fluid as a biomarker to assess disease severity and for treatment monitoring in patients with Mucopolysaccharidosis Type II: a position statement. |
|---|---|
| Authors: | Giugliani, Roberto1,2 (AUTHOR) rgiugliani@hcpa.edu.br, de Siqueira, Ana Cecília Menezes3 (AUTHOR), Santos, Emerson Santana4 (AUTHOR), Leão, Emília Katiane E. A.5 (AUTHOR), Carvalho, Gerson da Silva6 (AUTHOR), Santos, Mara Lúcia Schmitz Ferreira7 (AUTHOR), Raskin, Salmo8 (AUTHOR), Martins, Ana Maria9 (AUTHOR) |
| Source: | Orphanet Journal of Rare Diseases. 11/26/2024, Vol. 19 Issue 1, p1-6. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17501172 |
|---|---|
| DOI: | 10.1186/s13023-024-03463-9 |
